Pri-Med Podcasts

Latest Episodes:

Big and Strong: Vitamin D in the First Year of Life - Frankly Speaking Ep 309 Jan 02, 2023

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-309

Overview: Listen to this podcast to get answers to important questions about vitamin D supplementation in the first year of life. We will review a recent systematic review and meta-analysis on the relationship between vitamin D supplementation in the first year of life and outcomes, and we will discuss how these findings can be applied to your practice.

Episode resource links:

Nutrients; 2021 Feb 5;13(2):524. doi: 10.3390/nu13020524

Guest: Robert A. Baldor MD, FAAFP
Music Credit: Richard Onorato

Favorite Podcast of 2022 - Frankly Speaking Ep 308 Dec 26, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-308

Overview: In this episode, each podcaster will discuss the most impactful paper and podcast of the year.

Episode resource links:

Guest: Alan Ehrlich MD, FAAFP, Jillian Joseph, MPAS, PA-C, Susan Feeney, DNP, FNP-BC, NP-C, Mariyan L. Montaque, DNP, FNP-BC, Jill M. Terrien PhD, ANP-BC
Music Credit: Richard Onorato

Should There Be a Contraindication to CPR? - Frankly Speaking Ep 307 Dec 19, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-307

Overview: The COVID-19 epidemic resulted in overflowing ICUs and significant numbers of deaths among older adults. A recent study looked at the differences in outcomes between patients admitted with “No-code” vs “CPR” status and found no difference for high-risk individuals. Listen to this brief podcast to explore the data from this study and, in turn, give patients the information they need to make informed decisions regarding their desired code status on their advanced directives.

Guest: Robert A. Baldor MD, FAAFP
Music Credit: Richard Onorato

What To Do When Traditional Migraine Treatments Don’t Work: A Case Study Dec 15, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/case-study-traditional-migraine-treatment

Overview:

This podcast will focus on the case of a patient with a 30-year history of migraine who has tried numerous acute and preventive treatments. Faculty will discuss newer treatment options, including calcitonin gene-related peptide (CGRP) receptor antagonists (gepants), CGRP monoclonal antibodies, ditans, and neuromodulation.

Your Questions About Migraine Treatment Answered Dec 15, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/migraine-treatment-questions-answered

Overview:

In this podcast, Drs. Dawn Buse and Michael Ready will address questions about migraine treatment posed by Pri-Med learners during recent programs. Topics will include the proper use of calcitonin gene-related peptide (CGRP) monoclonal antibodies, nutraceuticals, acupuncture, and tetrahydrocannabinol.

Preventing Peanut Allergies—Are You Following the Recommendations? - Frankly Speaking Ep 306 Dec 12, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-306

Overview: In 2015, a landmark study, LEAP (Learning Early About Peanut Allergy), found that early introduction to peanuts, at 4 to 6 months, significantly reduced the incidence of peanut allergies in all children but especially in those at high risk for allergies. A recent survey of pediatric residents and attendings in a large academic center regarding knowledge and implementation of the guidelines uncovered a significant knowledge gap impacting the health of children. Join us as we discuss this gap and review the guidelines for preventing peanut allergies in infants and children.

Episode resource links:

Sandhu S, Hanono M, Nagarajan S, Vastardi MA. Knowledge assessment of early peanut introduction in a New York City population [published online ahead of print, 2022 Jun 18]. Ann Allergy Asthma Immunol. 2022;S1081-1206(22)00534-8. doi:10.1016/j.anai.2022.06.013
Greer FR, Sicherer SH, Burks AW, AAP COMMITTEE ON NUTRITION, AAP SECTION ON ALLERGY AND IMMUNOLOGY. The Effects of Early Nutritional Interventions on the Development of Atopic Disease in Infants and Children: The Role of Maternal Dietary Restriction, Breastfeeding, Hydrolyzed Formulas, and Timing of Introduction of Allergenic Complementary Foods. Pediatrics. 2019;143(4): e20190281
Togias A, Cooper SF, Acebal ML, et al. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Ann Allergy Asthma Immunol. 2017;118(2):166-173.e7. doi:10.1016/j.anai.2016.10.004
Fleischer DM, Sicherer S, Greenhawt M, et al. Consensus Communication on Early Peanut Introduction and Prevention of Peanut Allergy in High-Risk Infants. Pediatr Dermatol. 2016;33(1):103-106. doi:10.1111/pde.12685
Du Toit, G., Roberts, G., Sayre, P. H., Bahnson, H. T., Radulovic, S., Santos, A. F., Brough, H. A., Phippard, D., Basting, M., Feeney, M., Turcanu, V., Sever, M. L., Gomez Lorenzo, M., Plaut, M., Lack, G., & LEAP Study Team (2015). Randomized trial of peanut consumption in infants at risk for peanut allergy. The New England journal of medicine, 372(9), 803–813. https://doi.org/10.1056/NEJMoa1414850
Koplin JJ, Soriano VX, Peters RL. Real-World LEAP Implementation. Curr Allergy Asthma Rep. 2021;22(6):61-66. doi:10.1007/s11882-022-01032-3
https://www.fda.gov/food/cfsan-constituent-updates/fda-completes-review-notification-regarding-health-claim-related-peanut-allergies

Guest: Susan Feeney, DNP, FNP
Music Credit: Richard Onorato

Risks of Long-Term Use of PPIs - Frankly Speaking Ep 305 Dec 05, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-305

Overview: We will review the general treatment approach to gastroesophageal reflux disease (GERD) and the risks of using proton pump inhibitors (PPI) for long durations. In particular, we will examine a new study that links PPI use, in comparison with H2 receptor antagonist (H2RA) use, with a significant increase in the risk of gastric cancer. This episode will highlight the importance of looking at PPIs on a medication review and evaluating whether patients are taking them for longer than needed.

Episode resource links:

Abrahami D, McDonald EG, Schnitzer ME, et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022;71(1):16-24.

Guest: Jillian Joseph, MPAS, PA-C
Music Credit: Richard Onorato

Agitation in Alzheimer’s Dementia: What’s at Stake Nov 30, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™

CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/Podcast/agitation-in-alzheimers-dementia

Overview: Agitation is among the most common behavioral symptoms among patient with dementia, including Alzheimer’s dementia. It exacts a significant burden on patients because it is associated with not only greater morbidity and mortality, but also a faster cognitive and functional decline. It is also a leading predictor of which individuals with dementia will be transferred to residential care. This podcast provides an overview of the epidemiology, causes, and the burden of agitation in patients with Alzheimer’s dementia.

Selecting Medication for Depression: Do Genomics Matter? - Frankly Speaking Ep 304 Nov 28, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-304

Overview: Pharmacogenomic testing has been suggested as a way to personalize medicine, particularly where the metabolism of medications can vary significantly. Unfortunately, despite increasing use of this testing, there has been little evidence showing a benefit in clinical outcomes. Listen to this podcast to explore the data on clinical outcomes for pharmacogenetic testing and how to best select medication for patients with depression.

Episode resource links:

Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):151-161.

Guest: Alan Ehrlich MD, FAAFP
Music Credit: Richard Onorato

Time to Stop Recommending Vitamin D? - Frankly Speaking Ep 303 Nov 21, 2022

Show notes

Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-303

Overview: Millions of Americans take Vitamin D supplementation to prevent a variety of illnesses, from COVID-19 and osteoporosis to heart disease and cancer. While most studies have failed to show a benefit in preventing COVID-19, heart disease, and cancer, the evidence has been mixed, at best, in showing benefits for preventing bone fractures. Despite this, vitamin D supplementation remains popular for fracture prevention. Join us to review a study published in the New England Journal of Medicine that failed to find any benefits for preventing fractures.

Episode resource links:

N Engl J Med 2022;387:299-309. DOI: 10.1056/NEJMoa2202106

Guest: Robert A. Baldor MD, FAAFP
Music Credit: Richard Onorato

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected